Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Antibodies (Basel, Switzerland)
|
September 22, 2025
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study
Luca Bettolini, Stefano Bighetti, Silvia Mariel Ferrucci, et al.
Journal of Clinical Medicine
|
March 27, 2025
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes
Francesca Barei, Paolo Calzari, Elena Pezzolo, et al.
American Journal of Clinical Dermatology
|
February 24, 2025
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study
Francesco Leo, Michela Ortoncelli, Ruggero Cascio Ingurgio, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
June 5, 2025
<i>Letter:</i> Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Journal of the American Academy of Dermatology
|
January 10, 2024
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study
Gianluca Avallone, Luca Mastorino, Gianluca Tavoletti, et al.
Acta Dermato-Venereologica
|
April 15, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)
Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, et al.
The Journal of Dermatological Treatment
|
October 10, 2024
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)
Luigi Gargiulo, Luciano Ibba, Angela Alfano, et al.
Dermatology and Therapy
|
July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Dermatology and Therapy
|
May 29, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, et al.
Clinical and Experimental Dermatology
|
June 11, 2025
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched Study
Francesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Antibodies (Basel, Switzerland)
|
September 22, 2025
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study
Luca Bettolini, Stefano Bighetti, Silvia Mariel Ferrucci, et al.
Journal of Clinical Medicine
|
March 27, 2025
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes
Francesca Barei, Paolo Calzari, Elena Pezzolo, et al.
American Journal of Clinical Dermatology
|
February 24, 2025
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study
Francesco Leo, Michela Ortoncelli, Ruggero Cascio Ingurgio, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
June 5, 2025
<i>Letter:</i> Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Journal of the American Academy of Dermatology
|
January 10, 2024
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study
Gianluca Avallone, Luca Mastorino, Gianluca Tavoletti, et al.
Acta Dermato-Venereologica
|
April 15, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)
Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, et al.
The Journal of Dermatological Treatment
|
October 10, 2024
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)
Luigi Gargiulo, Luciano Ibba, Angela Alfano, et al.
Dermatology and Therapy
|
July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Dermatology and Therapy
|
May 29, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, et al.
Clinical and Experimental Dermatology
|
June 11, 2025
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched Study
Francesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, et al.
Page
of 6